双歧杆菌三联活菌联合铋剂四联疗法对消化性溃疡Hp感染患者血锌浓度的影响

Effect of bifidobacterium triple live bacteria treatment and bismuth based quadruple therapy on blood zinc concentration in patients with peptic ulcer Hp infection

目的探究双歧杆菌三联活菌联合铋剂四联疗法对消化性溃疡幽门螺杆菌(Hp)感染患者血锌浓度的影响。方法选择2015年3月至2016年11月我院收治的消化性溃疡Hp感染患者78例,根据随机数字表法将所有患者分为对照组和研究组,每组39例。对照组实施铋剂四联疗法治疗,研究组在此基础上予以双歧杆菌三联活菌治疗。比较两组患者的临床疗效,治疗前、后血锌浓度及用药安全性。结果研究组的治疗总有效率为94.87%,高于对照组的79.49%(P<0.05);治疗前,两组患者的血锌浓度比较,差异不显著(P>0.05);治疗7 d后,两组患者的血锌浓度较治疗前显著升高,且研究组高于对照组(P<0.05);研究组不良反应总发生率为10.26%,低于对照组的28.21%(P<0.05)。结论对消化性溃疡Hp感染患者实施双歧杆菌三联活菌联合铋剂四联疗法治疗,能提高临床疗效,改善血锌浓度,提高用药安全性,值得临床推广与应用。

Objective To investigate the effect of bifidobacterium triple live bacteria treatment and bismuth based quadruple therapy on blood zinc concentration in patients with peptic ulcer Hp infection. Methods A total of 78 patients with peptic ulcer of Hp infection in our hospital from March 2015 to November 2016 were divided into control group and research group by random number table, with 39 cases in each group. The control group was given bismuth based quadruple therapy; on this basis, the research group was given bifidobacterium triple live bacteria treatment. The clinical efficacy, blood zinc concentration before and after treatment, drug safety of the two groups were compared. Results The total effective rate of the research group was 94.87%, which was higher than 79.49% of the control group（P〈0.05）; before treatment, the difference in the blood zinc concentration between the two groups was not significant（P〉0.05）; at 7 d after treatment, the blood zinc concentration of the two groups significantly increased, and that of the research group was higher than the control group（P〈0.05）; the total incidence of adverse reactions of the research group was 10.26%, which was lower than 28.21% of the control group（P〈0.05）. Conclusion The bifidobacterium triple live bacteria treatment and bismuth based quadruple therapy in patients with peptic ulcer Hp infection can increase clinical efficacy, and improve blood zinc concentration and drug safety, which is worthy of clinical promotion and application.